This biomarker is also known as:
- early response factor Berg36,
- zinc finger protein 36, C3H1 type-like 1,
- Butyrate response factor 1,
- zinc finger protein 36, C3H type-like 1,
- zinc finger protein, C3H type, 36-like 1,
- Protein TIS11B,
- EGF-response factor 1,
- butyrate response factor 1,
View in BioMuta
ZFP36L1 is a member of the TIS11 family of early response genes, which are induced by various agonists such as the phorbol ester TPA and the polypeptide mitogen EGF. The ZFP36L1 gene is well conserved across species and has a promoter that contains motifs seen in other early-response genes. ZFP36L1 contains a putative zinc finger domain with a repeating cys-his motif. ZFP36L1 is believed to be a nuclear transcription factor most likely functioning in regulating the response to growth factors. Different isoforms encoded by alternatively spliced transcript variants have been isolated.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
No additional breast data available.
ZFP36L1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.